|
|
Phase II/III Randomized Study of Docetaxel With or Without Oblimersen (Bcl-2 Antisense Oligonucleotide; G3139 ) in Patients With Previously Treated Non-Small Cell Lung Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
GENTA-GN304 NCI-G01-2046, UCLA-0301058, NCT00030641
|
|
|
Objectives - Compare the survival of patients with non-small cell lung cancer treated with docetaxel with or without oblimersen (G3139).
- Compare the proportion of major antitumor responses in patients treated with these regimens.
- Compare the response duration and time to progression in patients treated with these regimens.
- Compare the safety and clinical benefit of these regimens, in terms of changes in performance status and tumor-related symptoms, in these patients.
- Compare the proportion of patients surviving 6 and 12 months after treatment with these regimens.
Entry Criteria Disease Characteristics:
- Diagnosis of non-small lung cancer
(NSCLC)
- Stage IIIB (malignant pleural/pericardial effusion)
or IV
- Relapsed or refractory disease
- Measurable disease that has not been irradiated
- Previously treated with 1, and only 1, cytotoxic chemotherapy regimen in the neoadjuvant,
adjuvant, or metastatic setting
- No untreated or symptomatic brain metastases or leptomeningeal disease
Prior/Concurrent Therapy:
Biologic therapy: - At least 3 weeks since prior cytokines or vaccine therapy for NSCLC
- At least 3 weeks since prior immunotherapy or biologic therapy for NSCLC
- No concurrent anticancer biologic therapy
Chemotherapy: - See Disease Characteristics
- At least 3 weeks since prior chemotherapy for NSCLC
- No prior docetaxel
- No other concurrent anticancer chemotherapy
Endocrine therapy: - No concurrent corticosteroids* except for the following conditions:
- CNS disease
- Underlying lung disease
[Note: *Dose must be stable or decreasing for at least 4 weeks before study participation] Radiotherapy: - See Disease Characteristics
- At least 3 weeks since prior radiotherapy for NSCLC
- No prior radiotherapy to 25% or more of bone marrow (e.g.,
whole pelvis)
- No concurrent anticancer radiotherapy
Surgery: - At least 3 weeks since prior surgery for NSCLC
- No prior organ allograft
Other: - Recovered from prior therapy
- Prior first-line epidermal growth factor receptors (EGFR) administered with cytotoxic therapy are allowed
- At least 3 weeks since prior investigational drugs
- At least 3 weeks since other prior therapy NSCLC
- No prior anticancer therapy subsequent to the first (and only) prior cytotoxic chemotherapy regimen
- No prior second-line EGFR therapy
- No prior oblimersen (G3139)
- No other concurrent investigational or anticancer therapies
- No concurrent anticoagulation therapy except for warfarin (1 mg/day) for central line prophylaxis
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - Absolute neutrophil count at least 1,500/mm3 (without growth
factor support)
- Platelet count at least 100,000/mm3
- No bleeding or coagulation disorder
Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal
(ULN)
- ALT and AST no greater than 2.5 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
- Albumin at least 3.0 g/dL
- PT no greater than 1.5 times ULN OR INR no greater than 1.3
- PTT no greater than 1.5 times ULN
- No chronic hepatitis
- No chronic cirrhosis
Renal: - Creatinine no greater than 1.5 times ULN
Cardiovascular: - No New York Heart Association class III or IV heart
disease
- No uncontrolled congestive heart failure
Pulmonary: - No severe pulmonary disease
- No requirement for oxygen due to pneumonectomy
- No severe pleural effusion secondary to NSCLC
Immunologic: - HIV negative
- No active infection
- No active autoimmune disease
Other: - No other concurrent active cancer
- No uncontrolled diabetes mellitus
- No uncontrolled seizure disorder
- No peripheral neuropathy grade 2 or greater
- No active peptic ulcer disease
- No other significant medical disease
- No intellectual, emotional, or physical disability that would
preclude study participation
- No neurologic disorders, overt psychosis, mental disability, or evidence of a limited capacity to give informed consent or to comply with study treatment
- No known hypersensitivity to phosphorothioate-containing oligonucleotides
- No history of hypersensitivity to drugs containing the excipient Tween 80 (polysorbate 80)
- Satisfactory venous access for multi-day continuous
infusion
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
Expected Enrollment A total of 280 patients (140 per treatment arm) will be accrued for this study. Outline This is a randomized, open-label, multicenter study. Patients are
stratified according to response to prior first-line chemotherapy regimen
(progression vs stable disease, partial response, or complete response), ECOG performance status (0-1 vs 2), and prior
paclitaxel treatment (yes vs no). Patients are randomized to 1 of 2 treatment
arms. - Arm I: Patients receive oblimersen (G3139) IV continuously on days 1-7 and
docetaxel IV over 1 hour on day 5. Treatment repeats every 21 days for up to
8 courses in the absence of disease progression or unacceptable
toxicity. Patients with responding or stable disease upon completion of 8 courses may receive 8 or more additional courses at physician's discretion.
- Arm II: Patients receive docetaxel IV over 1 hour on day 1. Treatment
repeats every 21 days for 8 courses in the absence of disease progression or
unacceptable toxicity. Upon completion of 8 courses, patients may continue to receive docetaxel off study at physician's discretion.
Patients are followed every 9 weeks for up to 18 months.
Trial Contact Information
Trial Lead Organizations Genta Incorporated | | | Deborah Braccia, Protocol chair | | | |
Registry Information | | Official Title | | Randomized Study of Docetaxel Versus Docetaxel Plus Genasense™ (G3139; Bcl-2 Antisense Oligonucleotide) in Patients with Previously Treated Non-Small Cell Lung Cancer | | Trial Start Date | | 2001-10-23 | | Registered in ClinicalTrials.gov | | NCT00030641 | | Date Submitted to PDQ | | 2001-12-13 | | Information Last Verified | | 2003-09-04 | | NCI Grant/Contract Number | | CA08748 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|